GPX4 is upregulated in many patients with lung cancers and causes resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), radiotherapy, and immune checkpoint inhibitors [15]. The gene discussed is EGFR; the disease is lung carcinoma.